EUCTR2012-001107-20-GB进行中（未招募）1 期
A Phase 2a Randomised, Double-Blind, Placebo-Controlled Repeat Dose Trial of the Activity of MDT-637 in Healthy Subjects Challenged with RSV-A (Memphis 37b) - Phase 2a trial of MDT-637 in healthy subject challenged with RSV.
MicroDose Therapeutx, Inc., a wholly owned subsidiary of Teva Pharmaceuticals Industries, Ltd.0 个研究点目标入组 143 人开始时间: 2013年7月23日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 143
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Age 18 to 45 years, inclusive.
- •2. In good health with no history of major medical conditions from medical history, physical examination, and routine laboratory tests as determined by the Investigator by a screening evaluation.
- •3. A Total body weight =50kg and a BMI >18. If the BMI is above 28 the subject may be included if the waist measurement is less than 94 cm (male), or less than 80 cm (female).
- •4. (a) Male subjects must use highly effective contraception consisting of two forms of birth control (one of which must be a barrier method) starting at entry to Quarantine and continue until the Day 28 follow-up visit.
- •(b) In addition, male subjects must not donate sperm following discharge from Quarantine until the Day 28 follow-up visit.
- •(c) Female subjects must be either:
- •- post-menopausal (defined as at least one year documented history without any menses/or post-menopausal females (confirmed by FSH test) prior to Screening or
- •- documented status as surgically sterile or post hysterectomy or
- •- if of childbearing potential, must have a negative urine pregnancy test at SSS and must be using highly effective contraception consisting of two forms of birth control (one of which must be a barrier method) starting at entry to Quarantine and continue until the Day 28 follow-up visit.
- •Acceptable forms of effective contraception include:
- •- Established use of oral, injected or implanted hormonal methods of contraception
- •- Placement of an intrauterine device (IUD) or intrauterine system (IUS).
- •- Barrier methods of contraception: Condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.
- •- Male sterilisation (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate). [For female subjects on the study, the vasectomised male partner should be the sole partner for that subject].
- •5. An informed consent document voluntarily signed and dated by the subject and investigator
- •6. Sero-suitable for Challenge Virus
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 96
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1. Subjects who have a significant history of any tobacco use at any time (= total 10 pack year history)
- •2. Subjects who are pregnant or breast feeding; or who are male and have a female partner who is pregnant, nursing, or is planning to become pregnant during the study period
- •3. Any history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrinological, haematological, hepatic, immunological, metabolic, urological, neurological, psychiatric, renal, and/or other major disease or malignancy, as judged by the medical investigator.
- •Eczema/Atopic Dermatitis: subjects with clinically mild eczema/atopic dermatitis may be included at the Investigator's discretion.
- •Psoriasis: patients with active psoriasis affecting less than 5% of the body's surface area for the past five years can be included at the Investigator's discretion. Patients with a history of completely resolved guttate psoriasis can be included.
- •Subjects with a diagnosis of a single mild or moderate depressive episode two or more years ago, with good evidence of preceding stressors and which resolved within approximately three months, may be included at the Investigator's discretion.
- •4. Abnormal pulmonary function in the opinion of the Investigator as evidenced by clinically significant abnormalities in spirometry.
- •5. History or evidence of autoimmune disease or known immunodeficiency of any cause.
- •6. Subjects with any history of asthma, COPD, pulmonary hypertension, reactive airway disease, or any chronic lung condition of any aetiology.
- •7. A history of childhood asthma before the age of 12 is acceptable provided the subject is asymptomatic without treatment. Patients with a single episode of wheezing after age 12 (lasting less than eight weeks) can be included at the Investigator's discretion provided the episode is more than four years ago and did not require a hospital admission and/or oral steroids.
- •8. Positive HIV, hepatitis B , or hepatitis C test.
- •9. Any significant abnormality altering the anatomy of the nose or nasopharynx.
- •10. Any clinically significant history of epistaxis.
- •11. Any nasal or sinus surgery within 6 months of inoculation.
- •12. Recurrent history of clinically significant autonomic dysfunction.
- •13. Any laboratory test or ECG, which is abnormal and deemed by the investigator(s) to be clinically significant.
- •14. Confirmed positive test for cotinine and /or drugs of abuse deemed by the Investigator to be clinically significant.
- •15. Unable to comply with study procedures including venous access deemed inadequate for the phlebotomy and cannulation demands of the study.
- •16. Any known allergies to the excipients in the Challenge Virus inoculum or investigational product. Specifically severe lactose intolerance.
- •17. Health care workers who work in units with severely immuno-compromised patients.
- •18. Presence of household member or close contact (for an additional two weeks after discharge from the isolation facility) who:
- •has known immunodeficiency
- •is receiving immunosuppressant medication
- •is undergoing or soon to undergo cancer che
研究者
相似试验
招募中
2 期
Study to Assess the Effectiveness and Safety of AZD4604 in Adult Patients with Uncontrolled Moderate-to-Severe Asthma – The AJAX StudyCTRI/2024/04/065120AstraZeneca AB
进行中（未招募）
1 期
Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABACTIS2023-506000-50-00Astrazeneca AB320
尚未招募
2 期
Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients with Sickle Cell DiseaseHaematological DisordersPACTR202206488890527Bausch Health America60
已完成
2 期
Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell DiseaseSickle Cell Disease patients with history of VOCsAnemia, Hemolytic, Congenital, Hematologic Diseases,LBCTR2022095104Bausch Health LLC9
进行中（未招募）
1 期
A Phase 2a Study of Efinopegdutide in Adults With Compensated Cirrhosis Secondary to Metabolic Dysfunction-Associated SteatohepatitisCTIS2024-510923-20-00Merck Sharp & Dohme LLC91